Spark Biomedical creates a subsidiary, Five Liters, to focus the initiative while taking advantage of the company’s experience in turning patents into FDA-approved products.

The companies partnered to design, develop and manufacture the medical device technology that provides a wearable neurostimulation solution for opioid withdrawal relief

The jointly run pilot clinical study is the first step in pioneering closed-loop opioid withdrawal detection and treatment 

A clinical trial in Dallas will test new technology that could help infants overcome withdrawal from exposure to opioids while in the womb.

Spark Biomedical created the FDA-approved Sparrow Therapy System. It’s essentially an earpiece that sends mild electrical pulses to the brain to help alleviate the withdrawal symptoms that patients go through while they’re detoxing, like insomnia, tremors, chills and sweating, bone pain, mood swings, and more.

The Medical University of South Carolina and UT Southwestern Medical Center join Spark Biomedical in Phase II clinical trial.

Spark Biomedical, Inc, the Hazelden Betty Ford Foundation, and Gaudenzia, Inc. Unite in Effort to Help Patients Reduce Relapse Risks and Sustain Recovery From Opioid Use Disorder

Spark Biomedical, Inc enlists the expertise of former Deputy Secretary of the U.S. Department of Health and Human Services (HHS), Eric D. Hargan, and his consulting firm, The Hargan Group, to help make novel withdrawal relief treatment more accessible and affordable for patients

D CEO and Dallas Innovates are proud to announce the finalists for its third annual Innovation Awards and Spark Biomedical is on the list of contenders for Startup Innovator of the Year.

FinPay LLC, a recognized leader in pre-care payments and patient engagement, announced an agreement with Spark Biomedical, Inc., a Texas-based medical device company and developer of the first FDA-cleared, drug-free, personalized, wearable neurostimulation solution for opioid withdrawal — the Sparrow Therapy System.